CITF Research Results

CITF Research Results2021-05-12T10:36:38-04:00

Workplace SARS-CoV-2 testing throughout the pandemic

Researchers from SeroTracker followed SARS-CoV-2 testing programs reported by 1,159 Canadian and 1,081 international employers across multiple sectors from March 1, 2020, to March 31, 2021. In a recent preprint, therefore not yet peer-reviewed, they report that fewer than 20% of high transmission workplaces had publicly disclosed a testing program. These workplaces represent retail and customer-facing environments, as well as indoor and mixed blue-collar [...]

July 13, 2021|Geographic & priority populations|

COVID-19 vaccination during pregnancy in Ontario

Pregnant individuals in Ontario have only been designated a priority population for COVID-19 vaccination since late April 2021. Researchers are now able to provide long-sought insights into vaccine uptake in this population. In a study supported by the VSRG and the CITF, Dr. Deshayne Fell and her team at the Better Outcomes Registry & Network (BORN) in Ontario are evaluating province-wide data on COVID-19 [...]

July 13, 2021|General vaccine surveillance|

Effectiveness of COVID-19 vaccines against VOCs in Canada

The race to vaccinate the world became more urgent with the emergence of variants of concern (VOCs). In a recent pre-print, not yet peer-reviewed, researchers from the Canadian Immunization Research Network (CIRN), including CITF-funded researchers Dr. Deshayne Fell, Dr. Jeff Kwong and Dr. Kumanan Wilson, estimated the effectiveness of vaccines given between December 2020 and May 2021 in protecting against symptomatic SARS-CoV-2 infection caused [...]

July 13, 2021|General vaccine surveillance|

Study reveals children and youth had highest rates of SARS-CoV-2 infection in Canada before third wave

Canada’s most representative study to date investigating how many Canadians have antibodies to SARS-CoV-2, the virus causing COVID-19, reveals a mere 2.6% of Canadians tested between November 2020 and April 2021 had developed antibodies resulting from a past infection. Another 1% of Canadians had antibodies due to vaccination, reflecting the fact that vaccination was not widely available during the survey period. This brings the total percentage of Canadians with some form of immunity before the third wave to 3.6%. These data come from Statistics Canada’s Canadian COVID-19 Antibody and Health Survey (CCAHS), done in partnership with Canada’s COVID-19 Immunity Task Force (CITF), the Public Health Agency of Canada, and Health Canada.

Extensive review of seroprevalence provides a global panorama on immunity

CITF-funded SeroTracker carried out a living systematic review of 968 seroprevalence studies that included 9.3 million participants in 74 countries. Their findings, published in PLOS One, suggest that the general population median seroprevalence worldwide was low (4.5%), but found important differences when comparing infection rates from diagnostic testing.   In this systematic review and meta-analysis, researchers from SeroTracker, along with several CITF members, searched [...]

June 29, 2021|Seroprevalence studies|

Largest international review of serosurveys, done by Canadians, suggests that the global population remains vulnerable to COVID-19

SeroTracker, a Canadian research group, has published the largest study to date on the global spread of SARS-CoV-2 in the journal PLOS One. The study examined antibody survey data, which were published from January to December 2020, from 9.3 million people in 74 countries and found that the number of people who had a SARS-COV-2 infection, although widely variable globally, remained fairly low in the general population.

Early results from a national study confirm antibody levels are stronger after receiving two doses

Initial preliminary results from the Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study, based on close to 6,000 dried blood spot samples collected between February 8 and May 17, 2021, show a high degree of variability in the level of antibodies produced by a single dose of a COVID-19 vaccine. These findings highlight the importance of accelerating second doses as the Delta variant continues to spread, particularly with the vast majority of Canadians having received only a single vaccine dose.

June 23, 2021|Immune science, Media Releases|

Immunity to SARS-CoV-2 persists for 9 months

The mechanisms of immune protection to SARS-CoV-2 are still unclear and researchers around the world are attempting to address this critical question. In a preprint, not yet peer-reviewed, Dr. Tania Watts from the University of Toronto, unravels the characteristics and extent of B and T cell responses of our immune system after recovery from COVID-19. She also compares the profile of these COVID-19 immune [...]

June 22, 2021|Immune science|

Interim results unveil Vancouver public school staff are not at higher risk of COVID-19 infection with mitigation measures that are in place

Drs. Pascal Lavoie and Louise C. Mâsse and their team at the University of British Columbia have released interim results, soon to be submitted for peer-review, suggesting that school staff are not at increased risk of SARS-CoV-2 infection at school, compared to in the community. The authors attribute this in part to the appropriate public health measures in place. Participants in their recent SARS-CoV-2 [...]

June 22, 2021|Seroprevalence studies|
Go to Top